{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:57:09Z","timestamp":1792789029374,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100022115","name":"Dutch Arthritis Association","doi-asserted-by":"publisher","award":["18-2-401"],"award-info":[{"award-number":["18-2-401"]}],"id":[{"id":"10.13039\/501100022115","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ard.2025.11.025","type":"journal-article","created":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T03:47:47Z","timestamp":1766288867000},"page":"761-770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Results of a 1-year randomised double-blind placebo-controlled trial with methotrexate 25 mg\/week in recently diagnosed polymyalgia rheumatica"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3911-3515","authenticated-orcid":false,"given":"Thomas E.","family":"Bolhuis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9125-1187","authenticated-orcid":false,"given":"Noortje E.S.E.P.","family":"Kooijman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3103-1374","authenticated-orcid":false,"given":"Diane E.","family":"Marsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2549-2713","authenticated-orcid":false,"given":"Gijs F.","family":"Snijders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9012-4079","authenticated-orcid":false,"given":"Alfons A.","family":"den Broeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7126-2209","authenticated-orcid":false,"given":"Nathan","family":"den Broeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3855-6763","authenticated-orcid":false,"given":"Aatke","family":"van der Maas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10411","key":"10.1016\/j.ard.2025.11.025_bib0001","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(23)01310-7","article-title":"Polymyalgia rheumatica","volume":"402","author":"Esp\u00edgol-Frigol\u00e9","year":"2023","journal-title":"Lancet."},{"issue":"10","key":"10.1016\/j.ard.2025.11.025_bib0002","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","article-title":"2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"5 suppl 68","key":"10.1016\/j.ard.2025.11.025_bib0003","first-page":"S143","article-title":"Glucocorticoid treatment of polymyalgia rheumatica","volume":"29","author":"Caporali","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"10.1016\/j.ard.2025.11.025_bib0004","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1136\/annrheumdis-2018-213883","article-title":"Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study","volume":"77","author":"Partington","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ard.2025.11.025_bib0005","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/annrheumdis-2021-221957","article-title":"Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial","volume":"81","author":"Boers","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"7-8","key":"10.1016\/j.ard.2025.11.025_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103590","article-title":"The pipeline of immunomodulatory therapies in polymyalgia rheumatica and giant cell arteritis: a systematic review of clinical trials","volume":"23","author":"Kawka","year":"2024","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.ard.2025.11.025_bib0007","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00296-017-3874-3","article-title":"Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database","volume":"38","author":"Albrecht","year":"2018","journal-title":"Rheumatol Int"},{"issue":"7","key":"10.1016\/j.ard.2025.11.025_bib0008","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","article-title":"Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial","volume":"141","author":"Caporali","year":"2004","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.ard.2025.11.025_bib0009","first-page":"624","article-title":"Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study","volume":"23","author":"Ferraccioli","year":"1996","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2025.11.025_bib0010","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/ard.55.4.218","article-title":"Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?","volume":"55","author":"van der Veen","year":"1996","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ard.2025.11.025_bib0011","first-page":"1550","article-title":"The use of methotrexate in polymyalgia rheumatica","volume":"23","author":"Feinberg","year":"1996","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.11.025_bib0012","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00296-020-04783-2","article-title":"Effect of add-on methotrexate in polymyalgia rheumatica patients flaring on glucocorticoids tapering: a retrospective study","volume":"41","author":"Marsman","year":"2021","journal-title":"Rheumatol Int"},{"issue":"9","key":"10.1016\/j.ard.2025.11.025_bib0013","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/ggi.13460","article-title":"Retrospective analysis of the usefulness of a protocol with high-dose methotrexate in polymyalgia rheumatica: results of a single-center cohort of 100 patients","volume":"18","author":"Quartuccio","year":"2018","journal-title":"Geriatr Gerontol Int"},{"issue":"9","key":"10.1016\/j.ard.2025.11.025_bib0014","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/imj.14779","article-title":"Efficacy of methotrexate in polymyalgia rheumatica in routine rheumatology clinical care","volume":"50","author":"Ruediger","year":"2020","journal-title":"Intern Med J"},{"issue":"7S suppl 2","key":"10.1016\/j.ard.2025.11.025_bib0015","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1097\/RHU.0000000000001414","article-title":"Usefulness of methotrexate in the reduction of relapses and recurrences in polymyalgia rheumatica: an observational study","volume":"26","author":"de la Torre","year":"2020","journal-title":"J Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.ard.2025.11.025_bib0016","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.11.025_bib0017","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s13063-022-06263-3","article-title":"PolyMyalgia rheumatica treatment with methotrexate in optimal dose in an early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial","volume":"23","author":"Marsman","year":"2022","journal-title":"Trials"},{"issue":"8","key":"10.1016\/j.ard.2025.11.025_bib0018","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2010.03.004","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"63","author":"Moher","year":"2010","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.ard.2025.11.025_bib0019","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/art.34356","article-title":"2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"64","author":"Dasgupta","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.ard.2025.11.025_bib0020","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7","article-title":"Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study","volume":"44","author":"van Ede","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.ard.2025.11.025_bib0021","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/art.22630","article-title":"Usefulness of the disease activity scores for polymyalgia rheumatica for predicting glucocorticoid dose changes: a study of 243 scenarios","volume":"57","author":"Binard","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.ard.2025.11.025_bib0022","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/ard.2008.088526","article-title":"Validity of the polymyalgia rheumatica activity score in primary care practice","volume":"68","author":"Binard","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.ard.2025.11.025_bib0023","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/ard.2003.011379","article-title":"A disease activity score for polymyalgia rheumatica","volume":"63","author":"Leeb","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ard.2025.11.025_bib0024","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/art.22771","article-title":"The polymyalgia rheumatica activity score in daily use: proposal for a definition of remission","volume":"57","author":"Leeb","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.11.025_bib0025","unstructured":"US Department of Health and Human Services NIoH NCI. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. 2017. p.p 3462-3465 https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf (Accessed July 22, 2025)."},{"issue":"suppl 9","key":"10.1016\/j.ard.2025.11.025_bib0026","article-title":"Results of a one year randomized double-blind placebo-controlled trial with methotrexate 25 mg per week for recently diagnosed polymyalgia rheumatica","volume":"76","author":"Bolhuis","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.11.025_bib0027","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ard.2025.05.087","article-title":"OP0064 randomized double-blind placebo-controlled trial of methotrexate 25mg weekly in newly diagnosed polymyalgia rheumatica","volume":"84","author":"Bolhuis","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2025.11.025_bib0028","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/annrheumdis-2021-221126","article-title":"Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2\/3 randomised controlled trial","volume":"81","author":"Bonelli","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.ard.2025.11.025_bib0029","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/jama.2022.15459","article-title":"Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial","volume":"328","author":"Devauchelle-Pensec","year":"2022","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.ard.2025.11.025_bib0030","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJMoa2303452","article-title":"Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper","volume":"389","author":"Spiera","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ard.2025.11.025_bib0031","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3899\/jrheum.150599","article-title":"Rapid and sustained response to tocilizumab in patients with polymyalgia rheumatica resistant or intolerant to glucocorticoids: a multicenter open-label study","volume":"43","author":"Toussirot","year":"2016","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2025.11.025_bib0032","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/rheumatology\/keae428","article-title":"Definitions of and instruments for disease activity, remission and relapse in polymyalgia rheumatica: a systematic literature review","volume":"64","author":"Bolhuis","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.ard.2025.11.025_bib0033","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10067-021-05819-z","article-title":"Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis","volume":"41","author":"Floris","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.ard.2025.11.025_bib0034","doi-asserted-by":"crossref","first-page":"e758","DOI":"10.1016\/S2665-9913(21)00245-9","article-title":"Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial","volume":"3","author":"Marsman","year":"2021","journal-title":"Lancet Rheumatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725045923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725045923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:19:36Z","timestamp":1780820376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725045923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0003496725045923"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.11.025","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of a 1-year randomised double-blind placebo-controlled trial with methotrexate 25 mg\/week in recently diagnosed polymyalgia rheumatica","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.11.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Alliance of Associations for Rheumatology (EULAR). Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}